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were performed after 0, 2, 4 and 6 h. A bactericidal
effect was deﬁned as a ‡ 3 log10 (99.9% killing)
reduction in CFU compared with the initial test
inoculum. Colony counts were determined and
averaged from each sample.
The results are presented in Fig. 1. Oﬂoxacin
and ciproﬂoxacin showed bactericidal activity
against E. coli J53 (pQR1) at concentrations two-,
four- and eight-fold higher than the MICs, begin-
ning after incubation for 2 h and 4 h for oﬂoxacin
and ciproﬂoxacin, respectively. These results
indicated that transfer of QnrA into E. coli J53
did not modify the bactericidal activity of oﬂoxa-
cin and ciproﬂoxacin.
Martı´nez-Martı´nez et al. [2] reported that QnrA
mayenhance selectionof higher levels of quinolone
resistance [2]. The low level of resistance conferred
by QnrA may allow the bacterial population to
reach a concentration at which secondary chromo-
somal mutations for higher levels of quinolone
resistance may occur. However, the bactericidal
activity of ﬂuoroquinolones remained unchanged.
Our results indicate that, in the absence of addi-
tional chromosome-encoded quinolone resistance
mechanisms, QnrA-positive enterobacterial iso-
lates may remain susceptible to the bactericidal
effect of ﬂuoroquinolones. Animal infection mod-
els, as well as clinical studies, may provide further
evidence to support these in-vitro results.
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Correct use of the term ‘pan-drug-resistant’
(PDR) Gram-negative bacteria
We congratulate Hsueh et al. for their recent
publication in CMI regarding ‘pan-drug-resistant’
nosocomial Pseudomonas aeruginosa infections [1].
However, we would like to express our disagree-
ment with the use of the term ‘pan-drug-resistant’
(PDR) in this article. We believe that this term
should not be used for Gram-negative bacteria
that are susceptible to polymyxins. This practice
causes confusion among clinicians because it
suggests an absence of antimicrobial agents for
the management of infections caused by these
bacteria, while a potential salvage option is
available in the form of intravenous polymyxins.
An isolate of P. aeruginosa should be deﬁned as
‘pan-drug-resistant’ if it is resistant to all seven
available anti-pseudomonal classes of antimicro-
bial agents, namely anti-pseudomonal penicillins,
cephalosporins, carbapenems, monobactams,
quinolones, aminoglycosides and polymyxins
[2]. Several recent studies have used the term
‘pan-drug-resistant’ despite the fact that the iso-
lates had not been tested for their susceptibility to
polymyxins [3–5]. For example, a mortality rate of
60% was reported in a study of patients with
‘pan-drug-resistant’ Acinetobacter baumannii infec-
tions from Taiwan; however, the isolates were not
tested for their in-vitro susceptibility to polymyx-
ins. Furthermore, no polymyxin was used to treat
the patient population studied [3,4]. Several stud-
ies have now shown that intravenous polymyxins
may be useful for the treatment of patients with
infections caused by Gram-negative bacteria with
in-vitro susceptibility to these antibiotics, even if
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the isolates are resistant to antimicrobial agents of
other classes.
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Serum procalcitonin levels in patients with
mild community-acquired pneumonia
Serum procalcitonin (PCT) has been described as
a useful parameter for distinguishing various
types of inﬂammation [1]. A recent study in
CMI [2] demonstrated the superiority of PCT for
the differential diagnosis of febrile neutropenia in
comparison with C-reactive protein. In order to
elucidate the value of PCT in comparison with
other parameters for diagnosis in patients with
mild community-acquired pneumonia, we con-
ducted a study in 116 consecutive patients
with community-acquired pneumonia who were
receiving oral antibiotic therapy. Patient demo-
graphics, medical history, signs and symptoms,
X-ray characteristics and laboratory parameters
were recorded. An aetiological diagnosis was
attempted by blood and sputum culture, tests
for Streptococcus pneumoniae (Binax, Portland, ME,
USA) and Legionella pneumophila (Biotest AG,
Dreieich, Germany) urinary antigens, and anti-
body tests for Mycoplasma pneumoniae (ELISA;
Serion Immundiagnostica, Wu¨rzburg, Germany),
Chlamydia pneumoniae (microimmunoﬂuorescence
test; MRL Diagnostics, Cypress, CA, USA) and
Legionella pneumophila (immunoﬂuorescence; loc-
ally prepared L. pneumophila serogroup 1–14 and
Legionella micdadei antigens) in paired samples.
Statistical analysis was performed using SPSS
v. 10.0 (SPSS Inc., Chicago, IL, USA) and Micro-
soft Excel 2000.
Complete data sets were available for 99
patients, and the aetiology was established for
62 patients. Patients with atypical (M. pneumoniae,
C. pneumoniae and L. pneumophila), typical
(S. pneumoniae, Haemophilus inﬂuenzae, Moraxella
catarrhalis) and unknown aetiology differed in
age (p 0.007), chills (p 0.042), dyspnoea (p 0.013),
bronchial breathing (p 0.008), PCT (p 0.021) and
log PCT (p < 0.0001). One of 42 patients with an
atypical aetiology had a PCT level > 0.5 lg ⁄L,
compared with nine of 15 patients in the group
with typical pneumonia. A substantial overlap
was observed between patients with pneumonia
of typical, atypical and unknown aetiology with
respect to C-reactive protein values, white blood
cell counts and the percentage of non-segmented
neutrophils, but not for PCT and log PCT values
(Fig. 1). In comparison with C-reactive protein,
white blood cell and non-segmented neutrophil
counts, only the area under the random operator
characteristic curve for PCT was signiﬁcantly
different from the diagonal line of no predictive
value (p 0.004). There was no difference in PCT
levels for patients classiﬁed in different risk
classes by Fine et al. [3]. The speciﬁcity of tests
for PCT levels in distinguishing between typical
and atypical pneumonia was highest with a cut-
off level of 0.48 lg ⁄L.
We conclude that measurement of PCT levels
seems to be a useful tool to rule out an atypical
aetiology of pneumonia and to limit the use of
broad-spectrum antibiotics. The results outlined
above support the use of PCT as a tool to help
discriminate between patients with lower respir-
atory tract infections who need antibiotics and
those who do not [4].
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